Renal side effects of VEGF-blocking therapy

NDT Plus

Volumn 3, Issue 2, 2010, Pages 172-175

  Mller Deile, Janina ^a   Brcker, Verena ^a   Grnwald, Viktor ^a   Hiss, Marcus ^a   Bertram, Anna ^a   Kubicka, Stefan ^a   Ganser, Arnold ^a   Haller, Hermann ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

bevacizumab; podocyturia; sunitinib; VEGF

Indexed keywords

ALBUMIN; BEVACIZUMAB; CREATININE; INTERLEUKIN 21; PODOCALYXIN; SUNITINIB; UREA; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; EOSINOPHIL; FOCAL GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; NEPHRITIS; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

EID: 77955964458     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp175     Document Type: Article

References (15)

1. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000; 2: 418-425
2. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28: 23S-30S
3. Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107-113
4. Halimi JM, Azizi M, Bobrie G et al. Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther 2008; 4: 602-615
5. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122: 322328
6. Achenbach J, Mengel M, Tossidou I et al. Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases. Nephrol Dial Transplant 2008; 23: 3138-3145
7. Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 2008; 8: 349-358
8. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007; 5: 341-344
9. Winn SK, Ellis S, Savage P et al. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009; 24: 673-675
10. Izzedine H, Brocheriou I, Rixe O et al. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007; 22
11. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular en- dothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
12. Garovic VD, Wagner SJ, Turner ST et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196
13. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Phy- siol Renal Physiol 2009; 296: F230-F241
14. Vogelmann SU, Nelson WJ, Myers BD et al. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48
15. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485